Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Retacrit™ (epoetin alfa-epbx) – New biosimilar approval
May 15, 2018 - The FDA announced the approval of Retacrit (epoetin alfa-epbx), Hospira/Pfizer’s biosimilar to Amgen’s Epogen® (epoetin alfa) and Janssen’s Procrit® (epoetin alfa).
